Neurocrine Biosciences (NBIX) Accounts Payables (2010 - 2026)

Neurocrine Biosciences has reported Accounts Payables for 17 years, with the latest figure at $773.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 62.67% year-over-year to $773.0 million; the trailing twelve-month figure through Mar 2026 stood at $773.0 million (up 62.67% YoY), and the FY2025 full-year result was $674.3 million, up 46.08% from the prior year.
• Accounts Payables for Q1 2026 stood at $773.0 million, up from $674.3 million in the prior quarter.
• The five-year high for Accounts Payables was $773.0 million in Q1 2026, with the low at $235.9 million in Q1 2022.
• Historically, Accounts Payables has averaged $439.6 million across 5 years, with a median of $417.2 million in 2024.
• Annual changes were most pronounced in 2023 — Accounts Payables surged 68.91% — and 2024, when it decreased 21.93%.
• Neurocrine Biosciences' Accounts Payables stood at $347.6 million in 2022, then grew by 29.11% to $448.8 million in 2023, then climbed by 2.85% to $461.6 million in 2024, then surged by 46.08% to $674.3 million in 2025, then climbed by 14.64% to $773.0 million in 2026.
• The last three Accounts Payables figures came in at $773.0 million (Q1 2026), $674.3 million (Q4 2025), and $584.3 million (Q3 2025), per Business Quant data.